Teva v. Novartis: Post-MedImmune Declaratory Judgment

Law360, New York (April 25, 2007, 12:00 AM EDT) -- On March 30, 2007 the Federal Circuit decided a case that may have significant impact on litigation in the pharmaceutical industry. In Teva Phamaceuticals USA Inc., v. Novartis Pharmaceuticals Corp., 2007 U.S. App. Lexis 7383 (Fed. Cir. 2007), the Federal Circuit reversed the district court’s dismissal of Teva’s suit seeking a declaration that its generic famciclovir product did not infringe several of Novartis’ patents relating to Famvir®. This holding represents yet another significant departure from prior Federal Circuit case law in the area of declaratory judgment...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.